Skip navigation

Uniting Payers, Providers and Manufacturers to Increase Market Access and Identify Value Ecosystems for Mature and Emerging Oncologic Therapies

February 26-27, 2019
  • San Francisco, CA

As the marketplace makes room for new and diverse treatment options it is more important than ever to have a clear “go-to-market strategy.” CBI’s 12th Annual Oncology Market Access Strategy Summit will bring together the various stakeholders involved in commercializing new oncologic therapies to ensure manufacturers have the tools needed to identify value networks early in the product lifecycle and ensure proper reimbursement channels are in place.

Previous Attendee Acclaim:

This conference has a great line-up of speakers and the conference atmosphere enabled excellent discussion.

Global Head, Pricing, Market Access & Policy, Biosimilars, Merck

The conference provided the knowledge I was anticipating and looking for. I appreciated the level of different topics that provided solutions to the issues and challenges faced today by manufacturers utilizing co-pay off-set strategies.

VP, Industry Relations & Managed Markets, City Drugs Specialty Pharmacy

Excellent appraisal of approaches and philosophies in market access and engagement.

Senior Director, Quality Strategic Consumer Group, Janssen

A cost-effective way to learn from thought leaders, peers and vendors in a topic area of interest. Especially useful at the beginning of the year to set performance goals and think of new approaches to explore during the year.

Assistant Director, Payer Marketing, Acorda Therapeutics

12th Annual Oncology Market Access Strategy Summit

Uniting Payers, Providers and Manufacturers to Increase Market Access and Identify Value Ecosystems for Mature and Emerging Oncologic Therapies

As the marketplace makes room for new and diverse treatment options it is more important than ever to have a clear “go-to-market strategy.” CBI’s 12th Annual Oncology Market Access Strategy Summit will bring together the various stakeholders involved in commercializing new oncologic therapies to ensure manufacturers have the tools needed to identify value networks early in the product lifecycle and ensure proper reimbursement channels are in place.

Previous Attendee Acclaim:

This conference has a great line-up of speakers and the conference atmosphere enabled excellent discussion.

Global Head, Pricing, Market Access & Policy, Biosimilars, Merck

The conference provided the knowledge I was anticipating and looking for. I appreciated the level of different topics that provided solutions to the issues and challenges faced today by manufacturers utilizing co-pay off-set strategies.

VP, Industry Relations & Managed Markets, City Drugs Specialty Pharmacy

Excellent appraisal of approaches and philosophies in market access and engagement.

Senior Director, Quality Strategic Consumer Group, Janssen

A cost-effective way to learn from thought leaders, peers and vendors in a topic area of interest. Especially useful at the beginning of the year to set performance goals and think of new approaches to explore during the year.

Assistant Director, Payer Marketing, Acorda Therapeutics